CDKN2A and lung carcinoma: A recent study by UT MD Anderson Cancer Center found that when KEAP1, SMARCA4, and CDKN2A co-mutate with KRAS-G12C, KRASG12Ci monotherapy is ineffective in treating patients with advanced lung cancer (54).